The New York Entrepreneur

Pfizer RSV vaccine for infants has ‘generally favorable’ safety data, FDA staff say

Read Time:7 Second

The FDA is slated to make a decision on whether to approve Pfizer’s shot in August, just before respiratory syncytial virus season in the fall. 

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Futures Movers: Oil prices head higher as traders weigh energy demand prospects
Next post : FTC sues to block Amgen’s acquisition of Horizon Therapeutics